A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer

BACKGROUND: Pre-clinical data indicate enhanced anti-tumour activity when combining recombinant human interleukin-21 (rIL-21), a class 1 cytokine, with cetuximab, a monoclonal antibody, targeting the epidermal growth factor receptor. This phase 1 trial assessed the safety and tolerability of escalat...

Descripción completa

Detalles Bibliográficos
Autores principales: Steele, N, Anthony, A, Saunders, M, Esmarck, B, Ehrnrooth, E, Kristjansen, P E G, Nihlén, A, Hansen, L T, Cassidy, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305963/
https://www.ncbi.nlm.nih.gov/pubmed/22315057
http://dx.doi.org/10.1038/bjc.2011.599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305963/
https://www.ncbi.nlm.nih.gov/pubmed/22315057
http://dx.doi.org/10.1038/bjc.2011.599

Ejemplares similares